Market Intelligence, Clinical Progress, and High-Purity Reagents for Ribosomal Stress & Diamond-Blackfan Anemia Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RPL11 ribosomal stress pathway research. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RPL11 WT & DBA-Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Includes RPS19-binding domain. |
View RPL11 Products |
| Gene Delivery | RPL11 ORF Lentivirus / Plasmid Full-length ORF with nuclear localization signal. For stable cell line construction. |
View RPL11 Products |
| Benchmark Ab | Anti-RPL11 Monoclonal Antibody Recombinant positive control for Western/IP. Epitope mapped to C-terminal domain. |
View RPL11 Products |
| Validator | RPL11 siRNA Set (3 Unique Sequences) For ribosomal stress checkpoint knockdown verification. >85% mRNA reduction. |
View RPL11 Products |
| Related Target: RPL5 | RPL5 (Ribosomal Protein L5) Synergistic ribosomal protein; heterodimer formation with RPL11 required for MDM2 binding. |
View RPL5 Products |
| Related Target: MDM2 | MDM2 (E3 Ubiquitin Ligase) Primary RPL11 interaction partner; p53 degradation pathway target. |
View MDM2 Products |
| Related Target: RPS19 | RPS19 (Ribosomal Protein S19) Shared Diamond-Blackfan anemia pathology; synthetic lethality screening partner. |
View RPS19 Products |
| Related Target: TP53 | TP53 (Tumor Suppressor p53) Downstream effector stabilized by the RPL11-MDM2 interaction; key node in nucleolar stress response. |
View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| DBA Mutation Functional Analysis (Structural instability) | Site-specific mutant proteins (RPL11 RPS19-binding interface variants) with Theoretical MW verification by Mass Spec |
| Ribosomal Assembly Validation (5S RNP complex) | RPL5/RPL11 heterodimer complex available; Co-expression in HEK293 for native folding |
| Nuclear Localization Verification | Full-length ORF lentivirus with native NLS; High-titer particles (>10^8 TU/mL) for localization studies |
| MDM2 Competitive Binding Assays | Endotoxin-controlled (<1 EU/µg) proteins for sensitive cell-based p53 activation assays |
Live RPL11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Diamond-Blackfan Anemia Clinical Trials
- ➤ Latest Ribosomal Stress & p53 Research
- ➤ RPL11 Mutation & Structural Studies
- ➤ Recent Patent Filings (Ribosome Biogenesis)
Global Clinical Landscape & Future Outlook
The RPL11 therapeutic paradigm is shifting from passive observation of ribosomopathies toward active modulation of the ribosomal stress checkpoint. As understanding of the RPL11-MDM2-p53 axis matures, pharmaceutical interest is converging on synthetic lethality strategies that exploit ribosomal biogenesis defects in cancer cells while sparing normal tissue. The emergence of Diamond-Blackfan anemia (DBA) gene therapy programs and targeted protein degradation approaches against ribosomal assembly factors marks RPL11 as a critical biomarker and mechanistic target for next-generation oncology and rare disease therapeutics. Concurrently, the race for oncology therapeutics targeting the nucleolar stress response is intensifying: RNA Pol I inhibitors (e.g., CX-5461) and small-molecule PPI modulators are advancing, with RPL11 acting as the central hub linking ribosome biogenesis to p53 activation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Stanford Medicine, Children's Hospital Boston; Rare Disease Biotechs | Diamond-Blackfan Anemia | Mutant vs WT Protein Stability Assays (Need DBA-variant antigens) |
| Small Molecule (MDM2 inhibitors) | Roche, Novartis, Daiichi Sankyo | Solid Tumors (p53 WT) | RPL11-MDM2 Binding Assays (Need full-length proteins with native NLS) |
| Synthetic Lethality Screen | Broad Institute, MD Anderson | Ribosomopathy Cancers | Ribosomal Protein Complex Formation (RPL5/RPL11 heterodimer validation) |
| Antisense Oligonucleotides | ProQR, Stoke Therapeutics | Ribosomalopathies | Knockdown Efficiency Verification (Need validated siRNA controls) |
| RNA Pol I Inhibitors | Academic Spin-offs | Hematological Malignancies | Biomarker Validation (Need Benchmark Abs and siRNA for pathway verification) |